Tagged with Gilead

Saudi Arabia Dr Eid Mansour, general manager of Gilead’s new Saudi affiliate, shares the strategic goals behind the creation of a strong direct presence in a region previously managed almost entirely through distributors and how these goals align with the kingdom’s Vision 2030 and the National Transformation Programme. He also outlines the…

China Since first establishing an affiliate in China back in 2017, Gilead Sciences has been able to introduce 11 innovative medicines to the Chinese market – eight of which have been included in the National Reimbursement Drug List – across HIV prevention & treatment, viral hepatitis, invasive fungal disease, and cancer.…

USA The Pharmaceutical Research and Manufacturers of America (PhRMA) has had a board reshake, naming Gilead Sciences Chairman and CEO Daniel O’Day as its new chair. The reorganisation comes after the industry group’s failed efforts to block the Inflation Reduction Act (IRA) and the departure of several high-profile members.   Gilead…

Global Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million people were living with the disease globally in 2022. HIV treatments has become more manageable and are reaching more patients…

Global After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the company’s global commercial strategy and operations for HIV, COVID-19, and emerging viruses, she discusses the company’s strides in HIV prevention…

UAE Over the past few decades, the UAE has worked hard to attract top global talent to fill the gaps that its small local population was unable to. While the high salaries on offer were previously the main attractor to the country, with workers often staying for a couple of years…

Hong Kong Based at Gilead Sciences’ Hong Kong hub, as VP & GM of Asia, Turkey, and the Middle East, American Dustin Haines oversees a vast region that includes the “Asia 5” territories Singapore, Malaysia, Taiwan, Hong Kong and South Korea and is the biggest of the company’s intercontinental areas with respect…

UAE With a welter of regulatory upgrades in the UAE and Saudi Arabia in recent years, patients in the Middle East’s leading countries now have wider and faster access to cutting-edge biopharmaceutical innovation than ever before. Here, four leading lights in the region’s pharmaceutical industry highlight some of the most important…

UAE 16-year Gilead veteran, Vítor Papão, recently left Europe to take on a new role within the company as general manager of the vast Middle East & Russia cluster. He discusses the particularities of the region, and the partnerships and initiatives Gilead is actively pursuing with local stakeholders.   We have…

UK A roundup of the latest UK healthcare, pharma and biotech news including AbbVie and Lilly’s departure from the country’s voluntary medicines pricing agreement, Moderna’s expanded footprint, UK biotech’s 2022 funding downturn and Gilead’s Yescarta approval from NICE.   Northern Ireland Medicines supply still ‘problematic and inefficient’ (BBC News) According to…

Italy After former CEO Pierluigi Antonelli abruptly announced his departure last month, the Italian mid-cap has signed on former Gilead leader, Jacopo Andreose, as its new chief executive.   [I am] looking forward to joining the Angelini team and helping to chart the next chapter for [Angelini] Pharma. Jacopo Andreose Abrupt…

Vietnam A roundup of recent pharma and healthcare news from Vietnam including Gilead’s viral hepatitis initiative, the country’s explosion of dengue fever cases and the investigation into Boston Scientific’s Vietnam operations.   Gilead initiative to improve viral hepatitis management in Vietnam and the Philippines (BioSpectrum Asia) Gilead Sciences has embarked on…